Abstract: The present invention is directed to the use of the peptide compound Pro-Ser-Hyp-Gly-Asp-Trp-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquid buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Pro-Ser-Hyp-Gly-Asp-Trp-OH optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent.

Abstract: The present invention is directed to the use of the peptide compound Pro-Leu-Gly-NH2 as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquid buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Pro-Leu-Gly-NH2 optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent.

Abstract: The present invention is directed to the use of the peptide compound Ac-Ser-Asp-Lys-Pro-Asp-Met-Ala-Glu-Ile-Glu-Lys-Phe-Asp-Lys-Ser-Lys-Leu-Lys-Lys-Thr-Glu-Thr-Gln-Glu-Lys-Asn-Pro-Leu-Pro-Ser-Lys-Glu-Thr-Ile-Glu-Gln-Glu-Lys-Gln-Ala-Gly-Glu-Ser-OH or its combination with the peptide Lys-Trp-Lys-Leu-Phe-Lys-Lys-Ile-Glu-Lys-Val-Gly-Gln-Asn-Ile-Arg-Asp-Gly-Ile-Ile-Lys-Ala-Gly-Pro-Ala-Val-Ala-Val-Val-Gly-Gln-Ala-Thr-Gln-Ile-Ala-Lys as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases.

Abstract: The present invention is directed to the use of the peptide compound Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2 as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilizate or liquide buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2 optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent.

Abstract: The present invention is directed to the use of the peptide compound Pyr-Leu-Gly-Pro-Gln-Gly-Pro-Pro-His-Leu-Val-Ala-Asp-Pro-Ser-Lys-Lys-Gln-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2 as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquid buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Pyr-Leu-Gly-Pro-Gln-Gly-Pro-Pro-His-Leu-Val-Ala-Asp-Pro-Ser-Lys-Lys-Gln-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2 optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent.

Abstract: The present invention is directed to the use of the peptide compound Tyr-Pro-Ile-Lys-Pro-Glu-Ala-Pro-Gly-Glu-Asp-Ala-Ser-Pro-Glu-Glu-Leu-Asn-Arg-Tyr-Tyr-Ala-Ser-Leu-Arg-His-Tyr-Leu-Asn-Leu-Val-Thr-Arg-Gln-Arg-Tyr-NH2 as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquide buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Tyr-Pro-Ile-Lys-Pro-Glu-Ala-Pro-Gly-Glu-Asp-Ala-Ser-Pro-Glu-Glu-Leu-Asn-Arg-Tyr-Tyr-Ala-Ser-Leu-Arg-His-Tyr-Leu-Asn-Leu-Val-Thr-Arg-Gln-Arg-Tyr-NH2 optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent.

Abstract: The present invention is directed to the use of the peptide compound Ala-Pro-Leu-Glu-Pro-Val-Tyr-Pro-Gly-Asp- Asn-Ala-Thr-Pro-Glu-Gln-Met-Ala-Gln-Tyr-Ala-Ala-Asp-Leu-Arg-Arg-Tyr-Ile-Asn-Met-Leu-Thr-Arg-Pro-Arg-Tyr-NH2 as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquid buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Ala-Pro-Leu-Glu-Pro-Val-Tyr-Pro-Gly-Asp-Asn- Ala-Thr-Pro-Glu-Gln-Met-Ala-Gln-Tyr-Ala-Ala-Asp-Leu-Arg-Arg-Tyr-Ile-Asn-Met-Leu-Thr-Arg-Pro-Arg-Tyr-NH2 optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent.

Abstract: The present invention is directed to the use of the peptide compound Gly-Pro-Glu-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquid buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Gly-Pro-Glu-OH optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent.

Abstract: The present invention is directed to the use of the peptide compound Ala-Arg-Leu-Asp-Val-Ala-Ser-Glu-Phe-Arg-Lys-Lys-Trp-Asn-Lys-Trp-Ala-Leu-Ser-Arg-NH2 as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquide buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Ala-Arg-Leu-Asp-Val-Ala-Ser-Glu-Phe-Arg-Lys-Lys-Trp-Asn-Lys-Trp-Ala-Leu-Ser-Arg-NH2 optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent.

Abstract: The present invention is directed to the use of the peptide compound Pyr-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-NHEt as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquid buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Pyr-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-NHEt optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent.

Abstract: The present invention is directed to the use of the peptide compound Tyr-Arg-Gln-Ser-Met-Asn-Asn-Phe-Gln-Gly-Leu-Arg-Ser-Phe-Gly-Cys-Arg-Phe-Gly-Thr-Cys-Thr-Val-Gln-Lys-Leu-Ala-His-Gln-Ile-Tyr-Gln-Phe-Thr-Asp-Lys-Asp-Lys-Asp-Asn-Val-Ala-Pro-Arg-Ser-Lys-Ile-Ser-Pro-Gln-Gly-Tyr-NH2 as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases.

Abstract: The present invention is directed to the use of the combination of the His-Pro-Leu-Gln-Lys-Thr-Tyr-OH and His-Ser-Asp-Gly-lle-Phe-Thr-Asp-Ser-Tyr-Ser-Arg-Tyr-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Ala-Ala-Val-Leu-NH2 as a therapeutic combination for prophylaxis and/or treatment of cancer, a heart and vascular disease, an infectious disease, a fibrotic disease, an inflammatory disease, a neurodegenerative disease, or an autoimmune disease.

Abstract: A suspension system for a wheeled vehicle is provided, the suspension system being adapted to support at least one wheel of the vehicle and comprising at least one shock absorbing device adapted to be activated as a result of the motion of the at least one wheel in a substantially vertical direction, the suspension system further comprising electrical power generating means in fluid connection with the at least one shock absorbing device so that the activation of said at least one shock absorbing device results in electrical power being generated. Furthermore, the suspension system comprises means for absorbing at least partially the electrical power generated, the absorption of electrical power resulting in the stiffness of said at least one shock absorbing device being varied as a function of the electrical power absorbed.

Abstract: A tilting suspension system is provided for two wheels (2, 3) of a vehicle (200) disposed on a common axle with the module comprising a rigid frame (17) adapted to be firmly fixed to the chassis of the vehicle so as to be tilted together with the whole vehicle and a tilting arm (14) pivotally linked to the rigid frame. The tilting of the rigid frame is obtained as a result of the counter torque arising when activating hydraulic actuating means (101, 102) pivotally interposed between the tilting arm (14) and the rigid frame (17), with the tilting arm being pivotally connected to shock absorbers (18). The tilting module further comprises suspension arms (10, 11, 12, 13) pivotally connected to the rigid frame, with the suspension arms supporting, in cooperation with supporting uprights, the two wheels thus allowing both tilting and steering of the two wheels. The hydraulic actuating means (101, 102) are actuated by a hydraulic pump (112) driven by an electric motor (108).

Abstract: The invention concerns a vehicle with a main body having a longitudinal axis, and with a tilting unit for tilting the main body relative to a vertical plane through the longitudinal axis, whereby the tilting unit comprises an actuator, an control unit and a power provision unit for providing a power transmitting medium via the control unit to the actuator, whereby the control unit is configured to control the power intake of the actuator, characterized in comprising at least two redundant tilting units.

Abstract: A tilting suspension system is provided for a vehicle comprising at least a first and a second wheel (2,3) disposed on a common axle, the module comprising a suspension system adapted to support the at least first and second wheels allowing both tilting and vertical displacement of the at least first and second wheels, said module comprising tilting means (14) pivotally connected to the suspension system, so that tilting of the tilting means results in the suspension system being tilted together with the at least first and second wheels, the tilting means being connected to the suspension system through first and second shock absorbing means, so that a vertical displacement of one or both of the first or second wheels (2, 3) results in a force being exerted on one or both of the first and second wheels, respectively, varying in a non-linear manner as a function of the vertical displacement of the at least first and second wheels.

Abstract: An electromechanical module is provided allowing performance of both the driving and the braking function on a single wheel. The electromechanical module according to the present invention comprises in particular electromechanical driving means and electromechanical braking means controlled by a single control unit, so that electrical power may be supplied to each of said electromechanical driving and braking means. Moreover, according to a particular embodiment of the present invention, electrical power may be collected from said driving means and supplied to said braking means.

Abstract: A tilting suspension system is provided for two wheels of a vehicle disposed on a common axle with a module comprising a rigid frame adapted to be firmly fixed to the chassis of the vehicle so as to be tilted together with the whole vehicle. The tilting of the rigid frame is obtained as a result of the counter torque arising when activating actuating means firmly fixed to the rigid frame, with the tilting means being pivotable connected to shock absorbers. The tilting module further comprises suspension arms usually connected to the rigid frame, with said suspension arms supporting, in cooperation with supporting uprights, the two wheels thus allowing both tilting and steering of the two wheels. Moreover, electric motors may be received in the hubs of the wheels, thus allowing the realization of driving, steering and tilting module adapted to be used either in hybrid vehicles or electrically driven vehicles.

Abstract: An electromechanical module for a four wheeled vehicle 15, wherein said electromechanical module comprises two electric motors 2 and 3 each adapted to be mechanically coupled to a corresponding one of the two wheels 4 and 5 disposed on a common axle of the vehicle. Moreover, said electromechanical module comprises a control unit 8, two power electronic units 6 and 7 and electrical connections 8a, 8b, 6a and 7a to electrically connect the control unit 8 to each of said power electronic units 6 and 7 as well as to connect each of said power electronic units 6 and 7 to a corresponding one of said two electric motors 2 and 3. The electromechanical module according to the present invention allows transfer of electrical power between said two electric motors 2 and 3, thus allowing mechanical torque to be transferred between said two wheels 4 and 5, resulting in the traction capability and the driving performance of the vehicle being improved.